Use of VKAs and NOACs as stroke prophylaxis in patients with atrial fibrillation - a review of the literature
DOI:
https://doi.org/10.12775/QS.2024.18.53903Keywords
VKA, NOAC, atrial fibrillation, stroke, anticoagulantsAbstract
Introduction and Purpose: Stroke is a common complication of one of the most common cardiac arrhythmias, atrial fibrillation. The aim of this study is to provide key information about these diseases and to compare the drugs used to prevent stroke.
Materials and methods: A literature search was conducted using the medical databases PubMed and Google Scholar. Articles were retrieved in English, employing the key words: “VKA “, „NOAC”, „atrial fibrillation”, „anticoagulants“ and „stroke” appropriate configurations.
Conclusions: According to the recommendations and available medical literature, the use of NOACs is usually the most appropriate choice for stroke prevention in patients with atrial fibrillation. However there are also clinical situations, in which the use of VKAs would be more appropriate.
References
Mutschler E, Geisslinger G, Kroemer H. K., Menzel S, Ruth P, Arzneimittelwirkungen-Pharmakologie, Klinische pharmakologie, Toxikologie wydanie Polskie IV
Katsanos A H, Kamel H, Healey J S, Hart R G, Stroke Prevention in Atrial Fibrillation: Looking Forward, Circulation (142,24) https://doi.org/10.1161/CIRCULATIONAHA.120.049768
Lau DH, Linz D, Sanders P. New Findings in Atrial Fibrillation Mechanisms. Card Electrophysiol Clin. 2019;11(4):563-571. doi:10.1016/j.ccep.2019.08.007
Morin DP, Bernard ML, Madias C, Rogers PA, Thihalolipavan S, Estes NA 3rd. The State of the Art: Atrial Fibrillation Epidemiology, Prevention, and Treatment. Mayo Clin Proc. 2016;91(12):1778-1810. doi:10.1016/j.mayocp.2016.08.022
Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019;105(24):1860-1867. doi:10.1136/heartjnl-2018-314267
Hu Z, Ding L, Yao Y. Atrial fibrillation: mechanism and clinical management. Chin Med J (Engl). 2023;136(22):2668-2676. doi:10.1097/CM9.0000000000002906
Goette A, Lendeckel U. Atrial Cardiomyopathy: Pathophysiology and Clinical Consequences. Cells. 2021;10(10):2605. Published 2021 Sep 30. doi:10.3390/cells10102605
Mason FE, Pronto JRD, Alhussini K, Maack C, Voigt N. Cellular and mitochondrial mechanisms of atrial fibrillation. Basic Res Cardiol. 2020;115(6):72. Published 2020 Nov 30. doi:10.1007/s00395-020-00827-7
Barthels D, Das H. Current advances in ischemic stroke research and therapies. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165260. doi:10.1016/j.bbadis.2018.09.012
Hindricks G, Potpara T, Dagres N, Arbelo E, Bax J, Blomström-Lundqvist C, Boriani G, Castella M, Dan G A, Dilaveris P, Fauchier L, Filippatos G, Kalman J M, Meir M, Lane D, Lebeau J-P, Lettino M, Lip G, Pinto F, Thomas G N, Valgimigli M, Gelder I, Putte B, Watkins C, ESC Scientific Document Group , 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC, European Heart Journal, Volume 42, Issue 5, 1 February 2021, Pages 373–498, https://doi.org/10.1093/eurheartj/ehaa612
Lee HL, Kim JT, Lee JS, et al. CHA2DS2-VASc score in acute ischemic stroke with atrial fibrillation: results from the Clinical Research Collaboration for Stroke in Korea. Sci Rep. 2021;11(1):793. Published 2021 Jan 12. doi:10.1038/s41598-020-80874-1
Chao TF, Potpara TS, Lip GYH. Atrial fibrillation: stroke prevention. Lancet Reg Health Eur. 2024;37:100797. Published 2024 Feb 1. doi:10.1016/j.lanepe.2023.100797
Lip GYH, Proietti M, Potpara T, et al. Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal. Europace. 2023;25(9):euad226. doi:10.1093/europace/euad226
Romiti GF, Pastori D, Rivera-Caravaca JM, et al. Adherence to the 'Atrial Fibrillation Better Care' Pathway in Patients with Atrial Fibrillation: Impact on Clinical Outcomes-A Systematic
Review and Meta-Analysis of 285,000 Patients. Thromb Haemost. 2022;122(3):406-414. doi:10.1055/a-1515-9630
Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955-962. doi:10.1016/S0140-6736(13)62343-0
Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017;14(11):627-628. doi:10.1038/nrcardio.2017.153
Methavigul K. Revised HAS-BLED score for bleeding prediction in atrial fibrillation patients with oral anticoagulants. J Arrhythm. 2022;38(3):380-385. Published 2022 Apr 5. doi:10.1002/joa3.12709
Wytyczne ESC 2020 dotyczące diagnostyki i leczenia migotania przedsionków opracowane we współpracy z European Association of Cardio Thoracic Surgery (EACTS)
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association [published correction appears in Eur Heart J. 2013 Mar;34(10):790] [published correction appears in Eur Heart J. 2013 Sep;34(36):2850-1]. Eur Heart J. 2012;33(21):2719-2747. doi:10.1093/eurheartj/ehs253
Moreno-Arribas J, Bertomeu-González V, Anguita-Sanchez M, et al. Choice of New Oral Anticoagulant Agents Versus Vitamin K Antagonists in Atrial Fibrillation: FANTASIIA Study. Journal of Cardiovascular Pharmacology and Therapeutics. 2016;21(2):150-156. doi:10.1177/1074248415596426
Silverio A, Maio M, Prota C, De Angelis E, Radano I, Citro R, Carrizzo A, Ciccarelli M, Vecchione C, Capodanno D, Galasso G, Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients, European Heart Journal - Cardiovascular Pharmacotherapy, Volume 7, Issue FI1, April 2021, Pages f20–f29, https://doi.org/10.1093/ehjcvp/pvz073
Wu VC, Wang CL, Gan ST, et al. Efficacy and safety of NOAC versus warfarin in AF patients with left atrial enlargement. PLoS One. 2020;15(12):e0243866. Published 2020 Dec 14. doi:10.1371/journal.pone.0243866
Breithardt G, Baumgartner H, Berkowitz SD, et al. Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban. Heart. 2016;102(13):1036-1043. doi:10.1136/heartjnl-2015-308120
Avezum A, Lopes RD, Schulte PJ, et al. Apixaban in Comparison With Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: Findings From the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Circulation. 2015;132(8):624-632. doi:10.1161/CIRCULATIONAHA.114.014807
Lee H, Hong JH, Seo KD. Long-term stroke and major bleeding risk in patients with non-valvular atrial fibrillation: A comparative analysis between non-vitamin K antagonist oral anticoagulants and warfarin using a clinical data warehouse. Front Neurol. 2023;14:1058781. Published 2023 Jan 26. doi:10.3389/fneur.2023.1058781
Eikelboom J, Weitz J Warfarin faring better: vitamin K antagonists beat rivaroxaban and apixaban in the INVICTUS and PROACT Xa trials Journal of Thrombosis and Haemostasis 21(11) 3067 - 3071 https://doi.org/10.1016/j.jtha.2023.06.036
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Grzegorz Jama, Weronika Kmiotek, Gabriela Różańska-Smuszkiewicz, Paweł Smuszkiewicz-Różański, Radosław Oronowicz, Ewelina Wesołek-Bielaska, Agnieszka Kuzio, Aleksandra Cieplińska, Kinga Ziojła-Lisowska, Zuzanna Piasecka
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 138
Number of citations: 0
